Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline
Sign Up to like & getrecommendations! Published in 2019 at "Haemophilia"
DOI: 10.1111/hae.13903
Abstract: The factor VIII mimetic emicizumab (Hemlibra, Hoffman‐la Roche, Basel, Switzerland) has a novel mode of action that affects the laboratory monitoring of patients receiving this treatment. read more here.
Keywords: coagulation tests; treatment united; treatment; laboratory coagulation ... See more keywords
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14664
Abstract: Acquired haemophilia A (AHA) is a rare and potentially life‐threatening bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII). Treatment entails achieving haemostasis with bypassing agents or factor replacement, and eradication of the… read more here.
Keywords: hemophilia retrospective; treatment acquired; retrospective review; emicizumab treatment ... See more keywords